-
Share
3,025 Posts.
570
16/02/21
11:22
Share
Much better investing in companies that are growing their revenues each Q and/or undergoing serious clinical trials with real results.
CAN don't fit into any category, far far from it. CAN has a name & reputation which no doubt is slowly being diminished.
$99k is revenue, that is so shocking after growing & run as a company for 4 years, worse than shocking.
The Long Term hold is such a poor reasoning for holding a stock, could say that with any underperforming stock.
-
